{"gene":"MGAT2","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2003,"finding":"MGAT2 (acyl-CoA:monoacylglycerol acyltransferase 2) encodes an enzyme that catalyzes the synthesis of diacylglycerol from monoacylglycerol and fatty acyl-CoA (MGAT activity); expression in insect or mammalian cells markedly increased MGAT activity proportional to MGAT2 protein level, and DAG production depended on substrate concentration.","method":"Heterologous expression in insect cells and mammalian cells (COS-7, Caco-2, AV-12); in vitro enzyme activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic assay with substrate dose-response, independently replicated in two papers (PMID:12621063 and PMID:12576479) using multiple cell systems","pmids":["12621063","12576479"],"is_preprint":false},{"year":2003,"finding":"MGAT2 also possesses an intrinsic acyl-CoA:diacylglycerol acyltransferase (DGAT) activity, providing an alternative pathway for triacylglycerol synthesis; this DGAT activity is distinguished from MGAT activity by detergent treatment (nonionic/zwitterionic detergents abolish DGAT but not MGAT activity). MGAT2 expressed in E. coli conclusively demonstrated both activities.","method":"Recombinant murine MGAT2 expressed in E. coli; in vitro enzyme activity assay with detergent treatment to distinguish MGAT vs DGAT activities","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro reconstitution with recombinant protein in E. coli plus detergent discrimination assay, single lab but two orthogonal methods","pmids":["12730219"],"is_preprint":false},{"year":2003,"finding":"MGAT2 displays broad fatty acyl-CoA substrate specificity with highest activity toward oleoyl-CoA and toward monoacylglycerols containing unsaturated fatty acyls; MGAT2 activity is stimulated by phosphatidylcholine, phosphatidylserine, and phosphatidic acid and inhibited by oleic acid and sphingosine.","method":"In vitro enzyme activity assay using MGAT2 expressed in COS-7 cells; substrate specificity panel and lipid cofactor modulation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — comprehensive in vitro substrate specificity assay, single lab","pmids":["12730219"],"is_preprint":false},{"year":1995,"finding":"The human MGAT2 gene (GnT-II) encodes a 447-amino acid type II transmembrane Golgi enzyme with a short N-terminal cytoplasmic domain, a 20-residue hydrophobic signal-anchor transmembrane domain, and a 418-residue C-terminal catalytic domain; the entire coding region is on a single exon and the gene maps to chromosome 14q21. Recombinant enzyme purified from baculovirus/Sf9 cells showed ~20 µmol/min/mg specific activity and the product was identified by 1H-NMR and mass spectrometry as the expected GlcNAc-transferred N-glycan.","method":"Genomic cloning, baculovirus/Sf9 expression, protein purification, in vitro enzyme assay, 1H-NMR, mass spectrometry, FISH chromosomal mapping","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — enzyme purification to near-homogeneity, product identity confirmed by NMR and MS, multiple orthogonal methods in one study","pmids":["7635144"],"is_preprint":false},{"year":1996,"finding":"Point mutations in the catalytic domain of MGAT2 (Ser→Phe and His→Arg in two unrelated CDG type II patients) caused decreased protein expression in baculovirus/insect cells and inactivation of GnT-II enzyme activity, establishing MGAT2 as the causal gene for CDGS type II (CDG-IIa) and demonstrating that the mutated residues are required for catalytic function.","method":"Patient mutation identification, baculovirus expression of mutant proteins, enzyme activity assay, restriction-endonuclease analysis of family members","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — active-site mutagenesis (naturally occurring) with direct enzyme activity assay confirming loss of function, validated in two unrelated patients","pmids":["8808595"],"is_preprint":false},{"year":2002,"finding":"Mgat2-null mice are deficient in GlcNAcT-II enzyme activity and complex N-glycan synthesis in tissues, resulting in severe gastrointestinal, hematologic, and osteogenic abnormalities and early post-natal lethality; kidney N-glycan analysis revealed a novel bisected hybrid N-glycan in which the bisecting GlcNAc was substituted with β1,4-galactose or Lewis(x), demonstrating the essential role of MGAT2 in complex N-glycan biosynthesis in vivo.","method":"Mgat2 homozygous deletion mouse model; enzyme activity assay in tissues; N-glycan structural analysis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with direct enzyme activity assay and N-glycan structural analysis confirming loss of complex N-glycan synthesis","pmids":["12417412"],"is_preprint":false},{"year":2014,"finding":"MGAT2 physically interacts with DGAT2 via co-immunoprecipitation and in situ proximity ligation assay; deletion mutagenesis showed the interaction depends on the two transmembrane domains of DGAT2. When co-expressed, MGAT2 and DGAT2 co-localize in the ER and on lipid droplets and co-expression increases TG storage compared with either enzyme alone, suggesting substrate channeling for TG biosynthesis.","method":"Co-immunoprecipitation, proximity ligation assay, deletion mutagenesis of DGAT2, chemical cross-linking (DSS), co-localization imaging, TG storage quantification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus proximity ligation assay plus mutagenesis plus functional TG storage readout, single lab but multiple orthogonal methods","pmids":["25164810"],"is_preprint":false},{"year":2009,"finding":"MGAT2 deficiency (MGAT2-KO mice) prevents hypertriglyceridemia and significantly suppresses the rise in plasma GIP following oral triglyceride loading, while GLP-1 and PYY responses remain comparable to wild-type, demonstrating that MGAT2-dependent triglyceride re-synthesis (and/or chylomicron secretion) is required for GIP release but not for GLP-1/PYY release after fat ingestion.","method":"MGAT2-KO mouse model; oral triglyceride tolerance test; plasma gut peptide measurements (GIP, GLP-1, PYY)","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with defined hormonal phenotype readout and comparison to DGAT1-KO, single lab","pmids":["19732742"],"is_preprint":false},{"year":2013,"finding":"Myeloid-specific deletion of Mgat2 in antigen-presenting cells (APCs) reduces multi-antennary complex N-glycans on the cell surface and prevents glycoantigen (polysaccharide) presentation and T cell activation in vitro and in vivo, without affecting protein antigen responses, TLR2 signaling, antigen uptake, or cellular homing to lymph nodes; this establishes that complex N-glycan branching on APCs regulates MHC class II-dependent glycoantigen presentation.","method":"Myeloid-specific Mgat2 conditional knockout mouse (LyzM-CRE); in vitro and in vivo T cell activation assays; antigen uptake assay; lymph node homing assay","journal":"Glycobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO with multiple defined functional readouts, single lab","pmids":["24310166"],"is_preprint":false},{"year":2000,"finding":"The human MGAT2 promoter contains functional Ets-binding sites; co-transfection of ets-1 or ets-2 expression plasmids with MGAT2 promoter-CAT reporter constructs in HepG2 or COS-1 cells stimulated promoter activity 2–4-fold. Mobility-shift assays and South-Western blots localized the functional Ets-binding site to one of four putative sites. Unlike the GnT-V promoter, the MGAT2 promoter is not activated by src or neu.","method":"Transient transfection reporter assay, electrophoretic mobility shift assay (EMSA), South-Western blot","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus reporter assay plus negative controls (src/neu non-activation), single lab","pmids":["10749681"],"is_preprint":false},{"year":1998,"finding":"The MGAT2 gene has multiple transcription initiation sites and lacks a TATA box but contains a CCAAT box and multiple Sp1 consensus sites in a GC-rich promoter typical of housekeeping genes; a region between -636 and -553 bp relative to the ATG is the main promoter region, as its deletion dramatically decreased reporter gene activity in transient transfection experiments.","method":"5'-RACE, RNase protection, 3'-RACE, transient transfection of promoter-CAT deletion constructs in HeLa cells","journal":"Glycoconjugate journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter deletion series in transfection assay plus 5'/3'-RACE mapping, single lab, multiple methods","pmids":["9579808"],"is_preprint":false},{"year":2024,"finding":"Conditional deletion of Mgat2 in spermatogonia (via Stra8-iCre) causes a block in spermatogenesis largely prior to round spermatid formation, leading to male infertility; Mgat2-null germ cells fail to bind L-PHA and GSA-II lectins (confirming loss of complex N-glycans), and RNA-seq showed downregulation of genes required for sperm formation. Western blot confirmed increased AKT and ERK1/2 signaling in Mgat2-null germ cells, distinct from the reduced ERK and unchanged AKT seen in Mgat1-null germ cells.","method":"Conditional KO mouse (Stra8-iCre); lectin binding assay; RNA-seq; Western blot for AKT and ERK1/2 phosphorylation; histology","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with multiple orthogonal readouts (lectin binding, transcriptomics, signaling pathway Western blot), single lab","pmids":["39364139"],"is_preprint":false},{"year":2024,"finding":"MGAT1 and MGAT2 form homo- and heteromeric complexes in the ER and Golgi of living mammalian cells; bioluminescence imaging using split-luciferase (NanoBiT) complementation detected both MGAT1-MGAT1 and MGAT1-MGAT2 interactions and visualized ER-to-Golgi transitions of these complexes.","method":"NanoBiT split-luciferase complementation assay; bioluminescence subcellular imaging in living cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — split-luciferase PPI assay with subcellular imaging, single lab, single method","pmids":["39083973"],"is_preprint":false}],"current_model":"MGAT2 encodes two distinct enzymatic activities depending on context: in the Golgi, it functions as UDP-GlcNAc:α-6-D-mannoside β-1,2-N-acetylglucosaminyltransferase II (GnT-II), an essential step in converting oligomannose to complex N-glycans (required for neurological development, immune glycoantigen presentation, and spermatogenesis); in the small intestine endoplasmic reticulum, it acts as an acyl-CoA:monoacylglycerol acyltransferase (MGAT) catalyzing diacylglycerol synthesis for triglyceride re-synthesis and dietary fat absorption, forming a physical complex with DGAT2 via DGAT2's transmembrane domains to channel lipid substrates for efficient TG biosynthesis, and modulating gut hormone (GIP) release and energy expenditure."},"narrative":{"mechanistic_narrative":"MGAT2 is a bifunctional gene whose product carries out two mechanistically distinct enzymatic activities in different subcellular and tissue contexts. In the Golgi it functions as N-acetylglucosaminyltransferase II (GnT-II), a 447-residue type II transmembrane enzyme with a short cytoplasmic tail, a signal-anchor transmembrane domain, and a C-terminal catalytic domain that transfers GlcNAc onto the α-6-mannose arm of N-glycans, the committed step converting oligomannose to complex N-glycans [PMID:7635144]. This activity is essential in vivo: Mgat2-null mice lose complex N-glycan synthesis and develop severe gastrointestinal, hematologic, and osteogenic defects with early postnatal lethality [PMID:12417412], and loss-of-function point mutations in the catalytic domain abolish GnT-II activity and cause congenital disorder of glycosylation type IIa (CDG-IIa) in humans [PMID:8808595]. Complex N-glycan branching generated by MGAT2 is required for distinct cellular programs: in antigen-presenting cells it enables MHC class II-dependent glycoantigen presentation and T-cell activation [PMID:24310166], and in spermatogonia it is required for progression through spermatogenesis, with its loss derepressing AKT and ERK1/2 signaling and blocking round spermatid formation [PMID:39364139]. Separately, MGAT2 acts in the intestinal ER as an acyl-CoA:monoacylglycerol acyltransferase that synthesizes diacylglycerol from monoacylglycerol and fatty acyl-CoA, with an additional intrinsic DGAT activity distinguishable by detergent sensitivity [PMID:12621063, PMID:12576479, PMID:12730219]. In this role it physically associates with DGAT2 through DGAT2's transmembrane domains, co-localizing at the ER and lipid droplets to channel substrates for triglyceride synthesis [PMID:25164810], and MGAT2-dependent triglyceride re-synthesis is required for postprandial GIP secretion after dietary fat [PMID:19732742].","teleology":[{"year":1995,"claim":"Established the molecular identity, domain architecture, and chromosomal locus of the glycosyltransferase GnT-II and confirmed its catalytic product, defining the enzyme that commits N-glycans to the complex pathway.","evidence":"Genomic cloning, baculovirus/Sf9 purification, in vitro assay, NMR/MS product identification, and FISH mapping","pmids":["7635144"],"confidence":"High","gaps":["No atomic structure of the catalytic domain","Mechanism of acceptor mannose-arm recognition not resolved"]},{"year":1996,"claim":"Linked MGAT2 to human disease by showing catalytic-domain point mutations inactivate GnT-II, establishing it as the causal gene for CDG type IIa.","evidence":"Patient mutation identification with baculovirus expression of mutant proteins and enzyme activity assays in two unrelated families","pmids":["8808595"],"confidence":"High","gaps":["Genotype-phenotype range across CDG-IIa patients not addressed","How partial loss of branching produces specific clinical features unknown"]},{"year":1998,"claim":"Characterized the MGAT2 promoter as a TATA-less, GC-rich housekeeping-type promoter, addressing how the gene is constitutively transcribed.","evidence":"5'/3'-RACE, RNase protection, and promoter-CAT deletion series in HeLa cells","pmids":["9579808"],"confidence":"Medium","gaps":["Tissue-specific regulation not addressed","Identity of trans-acting factors at the core promoter not resolved here"]},{"year":2000,"claim":"Identified Ets transcription factors as activators of MGAT2 transcription and distinguished its regulation from GnT-V, beginning to define upstream control of branching enzyme expression.","evidence":"Reporter co-transfection, EMSA, and South-Western blot with src/neu negative controls in HepG2/COS-1 cells","pmids":["10749681"],"confidence":"Medium","gaps":["Physiological contexts driving Ets-dependent induction unknown","Only one of four candidate Ets sites mapped as functional"]},{"year":2002,"claim":"Demonstrated in vivo that MGAT2 is indispensable for complex N-glycan biosynthesis and organismal viability, and revealed compensatory novel glycan structures in its absence.","evidence":"Mgat2-null mouse with tissue enzyme assays and kidney N-glycan structural analysis","pmids":["12417412"],"confidence":"High","gaps":["Tissue-specific contributions to lethality not dissected","Mechanism by which bisected hybrid glycans arise not detailed"]},{"year":2003,"claim":"Revealed an entirely separate lipid-metabolic activity, showing MGAT2 catalyzes diacylglycerol synthesis (MGAT activity) and harbors an additional intrinsic DGAT activity, reframing the gene as bifunctional.","evidence":"Heterologous expression in insect/mammalian cells and recombinant E. coli protein with in vitro assays, detergent discrimination, and substrate specificity/cofactor panels","pmids":["12621063","12576479","12730219"],"confidence":"High","gaps":["How a single protein partitions between Golgi glycosyltransfer and ER acyltransferase functions is unexplained","Physiological relevance of the intrinsic DGAT activity in vivo not established"]},{"year":2009,"claim":"Connected MGAT2-dependent triglyceride re-synthesis to postprandial endocrine signaling, showing it is selectively required for GIP but not GLP-1/PYY secretion after dietary fat.","evidence":"MGAT2-KO mouse oral triglyceride tolerance test with plasma gut peptide measurements","pmids":["19732742"],"confidence":"Medium","gaps":["Whether the effect is due to TG re-synthesis per se or chylomicron secretion not separated","Cell-autonomous role in enteroendocrine cells not tested"]},{"year":2013,"claim":"Defined a function for complex N-glycan branching in immunity, showing MGAT2-dependent branching on antigen-presenting cells is required for MHC class II-dependent glycoantigen presentation.","evidence":"Myeloid-specific (LyzM-Cre) conditional Mgat2 knockout with T-cell activation, antigen uptake, and homing assays","pmids":["24310166"],"confidence":"Medium","gaps":["Which surface glycoproteins mediate the effect not identified","Mechanism linking branching to glycoantigen loading not resolved"]},{"year":2014,"claim":"Provided a structural mechanism for efficient triglyceride synthesis by showing MGAT2 physically partners with DGAT2 via DGAT2 transmembrane domains, supporting substrate channeling at the ER/lipid droplet.","evidence":"Reciprocal Co-IP, proximity ligation, DSS cross-linking, DGAT2 deletion mutagenesis, co-localization imaging, and TG storage quantification","pmids":["25164810"],"confidence":"High","gaps":["Direct evidence of metabolite channeling (vs. co-localization) not shown","Stoichiometry and architecture of the complex unknown"]},{"year":2024,"claim":"Extended the in vivo importance of MGAT2 branching to spermatogenesis and revealed that loss alters intracellular signaling, distinguishing MGAT2 from MGAT1.","evidence":"Stra8-iCre conditional KO with lectin binding, RNA-seq, histology, and Western blot for AKT/ERK1/2","pmids":["39364139"],"confidence":"Medium","gaps":["Glycoprotein substrates controlling germ cell signaling not identified","Causal link between altered AKT/ERK and the spermatogenic block not established"]},{"year":2024,"claim":"Began to define the supramolecular organization of branching enzymes by detecting MGAT1-MGAT2 hetero- and homomeric complexes and their ER-to-Golgi trafficking in living cells.","evidence":"NanoBiT split-luciferase complementation with bioluminescence subcellular imaging","pmids":["39083973"],"confidence":"Medium","gaps":["Single-method PPI evidence without orthogonal validation","Functional consequence of MGAT1-MGAT2 heteromers for glycan processing unknown"]},{"year":null,"claim":"How a single MGAT2 polypeptide is partitioned and regulated between its Golgi glycosyltransferase role and its ER lipid acyltransferase role remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No mechanism reconciling dual localization and dual catalytic functions","No structural model integrating GnT-II and MGAT/DGAT activities","Relative physiological weighting of the two functions across tissues unquantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[3,0,1]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[3,12]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[6,12]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3]}],"complexes":["MGAT2-DGAT2 complex","MGAT1-MGAT2 heteromer"],"partners":["DGAT2","MGAT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q10469","full_name":"Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase","aliases":["Beta-1,2-N-acetylglucosaminyltransferase II","GlcNAc-T II","GNT-II","Mannoside acetylglucosaminyltransferase 2","N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase II"],"length_aa":447,"mass_kda":51.5,"function":"Plays an essential role in protein N-glycosylation. Catalyzes the transfer of N-acetylglucosamine (GlcNAc) onto the free terminal mannose moiety in the core structure of the nascent N-linked glycan chain, giving rise to the second branch in complex glycans","subcellular_location":"Golgi apparatus membrane","url":"https://www.uniprot.org/uniprotkb/Q10469/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MGAT2","classification":"Not Classified","n_dependent_lines":56,"n_total_lines":1208,"dependency_fraction":0.046357615894039736},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MGAT2","total_profiled":1310},"omim":[{"mim_id":"610270","title":"MONOACYLGLYCEROL O-ACYLTRANSFERASE 2; MOGAT2","url":"https://www.omim.org/entry/610270"},{"mim_id":"602616","title":"ALPHA-1,6-@MANNOSYL-GLYCOPROTEIN BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE; MGAT2","url":"https://www.omim.org/entry/602616"},{"mim_id":"212066","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIa; CDG2A","url":"https://www.omim.org/entry/212066"},{"mim_id":"160995","title":"ALPHA-1,3-@MANNOSYL-GLYCOPROTEIN BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE; MGAT1","url":"https://www.omim.org/entry/160995"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Golgi apparatus","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MGAT2"},"hgnc":{"alias_symbol":["GNT-II"],"prev_symbol":[]},"alphafold":{"accession":"Q10469","domains":[{"cath_id":"3.90.550.10","chopping":"84-444","consensus_level":"high","plddt":95.0607,"start":84,"end":444}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q10469","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q10469-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q10469-F1-predicted_aligned_error_v6.png","plddt_mean":84.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MGAT2","jax_strain_url":"https://www.jax.org/strain/search?query=MGAT2"},"sequence":{"accession":"Q10469","fasta_url":"https://rest.uniprot.org/uniprotkb/Q10469.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q10469/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q10469"}},"corpus_meta":[{"pmid":"12621063","id":"PMC_12621063","title":"MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12621063","citation_count":164,"is_preprint":false},{"pmid":"8808595","id":"PMC_8808595","title":"Mutations in the MGAT2 gene controlling complex N-glycan synthesis cause carbohydrate-deficient glycoprotein syndrome type II, an autosomal recessive disease with defective brain development.","date":"1996","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8808595","citation_count":129,"is_preprint":false},{"pmid":"12576479","id":"PMC_12576479","title":"Cloning and functional characterization of a mouse intestinal acyl-CoA:monoacylglycerol acyltransferase, MGAT2.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12576479","citation_count":115,"is_preprint":false},{"pmid":"25164810","id":"PMC_25164810","title":"Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25164810","citation_count":69,"is_preprint":false},{"pmid":"7635144","id":"PMC_7635144","title":"The human UDP-N-acetylglucosamine: alpha-6-D-mannoside-beta-1,2- N-acetylglucosaminyltransferase II gene (MGAT2). Cloning of genomic DNA, localization to chromosome 14q21, expression in insect cells and purification of the recombinant protein.","date":"1995","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7635144","citation_count":64,"is_preprint":false},{"pmid":"19732742","id":"PMC_19732742","title":"Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19732742","citation_count":55,"is_preprint":false},{"pmid":"12730219","id":"PMC_12730219","title":"Properties of the mouse intestinal acyl-CoA:monoacylglycerol acyltransferase, MGAT2.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12730219","citation_count":52,"is_preprint":false},{"pmid":"36323235","id":"PMC_36323235","title":"MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.","date":"2022","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36323235","citation_count":41,"is_preprint":false},{"pmid":"21734185","id":"PMC_21734185","title":"Deficiency of MGAT2 increases energy expenditure without high-fat feeding and protects genetically obese mice from excessive weight gain.","date":"2011","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21734185","citation_count":39,"is_preprint":false},{"pmid":"12417412","id":"PMC_12417412","title":"Mice with a homozygous deletion of the Mgat2 gene encoding UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,2-N-acetylglucosaminyltransferase II: a model for congenital disorder of glycosylation type IIa.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12417412","citation_count":32,"is_preprint":false},{"pmid":"14652025","id":"PMC_14652025","title":"Evidence for alternative splicing and developmental regulation of the Drosophila melanogaster Mgat2 (N-acetylglucosaminyltransferase II) gene.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14652025","citation_count":17,"is_preprint":false},{"pmid":"29986142","id":"PMC_29986142","title":"Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29986142","citation_count":16,"is_preprint":false},{"pmid":"25315695","id":"PMC_25315695","title":"MGAT2 deficiency and vertical sleeve gastrectomy have independent metabolic effects in the mouse.","date":"2014","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25315695","citation_count":12,"is_preprint":false},{"pmid":"25598079","id":"PMC_25598079","title":"Cell-based assay of MGAT2-driven diacylglycerol synthesis for profiling inhibitors: use of a stable isotope-labeled substrate and high-resolution LC/MS.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25598079","citation_count":11,"is_preprint":false},{"pmid":"33044030","id":"PMC_33044030","title":"Immune dysfunction in MGAT2-CDG: A clinical report and review of the literature.","date":"2020","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/33044030","citation_count":10,"is_preprint":false},{"pmid":"10749681","id":"PMC_10749681","title":"Regulation of expression of the human beta-1,2-N-acetylglucosaminyltransferase II gene (MGAT2) by Ets transcription factors.","date":"2000","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/10749681","citation_count":9,"is_preprint":false},{"pmid":"9579808","id":"PMC_9579808","title":"Transcriptional regulation of the human UDP-GlcNAc:alpha-6-D-mannoside beta-1-2-N-acetylglucosaminyltransferase II gene (MGAT2) which controls complex N-glycan synthesis.","date":"1998","source":"Glycoconjugate journal","url":"https://pubmed.ncbi.nlm.nih.gov/9579808","citation_count":9,"is_preprint":false},{"pmid":"24310166","id":"PMC_24310166","title":"Mgat2 ablation in the myeloid lineage leads to defective glycoantigen T cell responses.","date":"2013","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/24310166","citation_count":8,"is_preprint":false},{"pmid":"27146521","id":"PMC_27146521","title":"Dendritic cell-specific Mgat2 knockout mice show antigen presentation defects but reveal an unexpected CD11c expression pattern.","date":"2016","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27146521","citation_count":6,"is_preprint":false},{"pmid":"26210160","id":"PMC_26210160","title":"Identification of 2-[2-(4-tert-butylphenyl)ethyl]-N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide (29) as an orally available MGAT2 inhibitor.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26210160","citation_count":5,"is_preprint":false},{"pmid":"39788365","id":"PMC_39788365","title":"Exploring the relationship between MGAT2 and glioblastoma: A Mendelian Randomization and bioinformatics approach.","date":"2025","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/39788365","citation_count":2,"is_preprint":false},{"pmid":"39083973","id":"PMC_39083973","title":"Subcellular imaging of MGAT1/MGAT2 homo- and heteromers in living cells using bioluminescence microscopy.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39083973","citation_count":2,"is_preprint":false},{"pmid":"26936050","id":"PMC_26936050","title":"Identification of 2-[2-(4-tert-Butylphenyl)ethyl]-N-[4-(3-cyclopentylpropyl)-2-fluorophenyl]-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide as an Orally Active MGAT2 Inhibitor.","date":"2016","source":"Chemical & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/26936050","citation_count":2,"is_preprint":false},{"pmid":"39364139","id":"PMC_39364139","title":"Deletion of Mgat2 in spermatogonia blocks spermatogenesis.","date":"2024","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/39364139","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14238,"output_tokens":3731,"usd":0.04934,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11345,"output_tokens":3769,"usd":0.075475,"stage2_stop_reason":"end_turn"},"total_usd":0.124815,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"MGAT2 (acyl-CoA:monoacylglycerol acyltransferase 2) encodes an enzyme that catalyzes the synthesis of diacylglycerol from monoacylglycerol and fatty acyl-CoA (MGAT activity); expression in insect or mammalian cells markedly increased MGAT activity proportional to MGAT2 protein level, and DAG production depended on substrate concentration.\",\n      \"method\": \"Heterologous expression in insect cells and mammalian cells (COS-7, Caco-2, AV-12); in vitro enzyme activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic assay with substrate dose-response, independently replicated in two papers (PMID:12621063 and PMID:12576479) using multiple cell systems\",\n      \"pmids\": [\"12621063\", \"12576479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MGAT2 also possesses an intrinsic acyl-CoA:diacylglycerol acyltransferase (DGAT) activity, providing an alternative pathway for triacylglycerol synthesis; this DGAT activity is distinguished from MGAT activity by detergent treatment (nonionic/zwitterionic detergents abolish DGAT but not MGAT activity). MGAT2 expressed in E. coli conclusively demonstrated both activities.\",\n      \"method\": \"Recombinant murine MGAT2 expressed in E. coli; in vitro enzyme activity assay with detergent treatment to distinguish MGAT vs DGAT activities\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro reconstitution with recombinant protein in E. coli plus detergent discrimination assay, single lab but two orthogonal methods\",\n      \"pmids\": [\"12730219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MGAT2 displays broad fatty acyl-CoA substrate specificity with highest activity toward oleoyl-CoA and toward monoacylglycerols containing unsaturated fatty acyls; MGAT2 activity is stimulated by phosphatidylcholine, phosphatidylserine, and phosphatidic acid and inhibited by oleic acid and sphingosine.\",\n      \"method\": \"In vitro enzyme activity assay using MGAT2 expressed in COS-7 cells; substrate specificity panel and lipid cofactor modulation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — comprehensive in vitro substrate specificity assay, single lab\",\n      \"pmids\": [\"12730219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human MGAT2 gene (GnT-II) encodes a 447-amino acid type II transmembrane Golgi enzyme with a short N-terminal cytoplasmic domain, a 20-residue hydrophobic signal-anchor transmembrane domain, and a 418-residue C-terminal catalytic domain; the entire coding region is on a single exon and the gene maps to chromosome 14q21. Recombinant enzyme purified from baculovirus/Sf9 cells showed ~20 µmol/min/mg specific activity and the product was identified by 1H-NMR and mass spectrometry as the expected GlcNAc-transferred N-glycan.\",\n      \"method\": \"Genomic cloning, baculovirus/Sf9 expression, protein purification, in vitro enzyme assay, 1H-NMR, mass spectrometry, FISH chromosomal mapping\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — enzyme purification to near-homogeneity, product identity confirmed by NMR and MS, multiple orthogonal methods in one study\",\n      \"pmids\": [\"7635144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Point mutations in the catalytic domain of MGAT2 (Ser→Phe and His→Arg in two unrelated CDG type II patients) caused decreased protein expression in baculovirus/insect cells and inactivation of GnT-II enzyme activity, establishing MGAT2 as the causal gene for CDGS type II (CDG-IIa) and demonstrating that the mutated residues are required for catalytic function.\",\n      \"method\": \"Patient mutation identification, baculovirus expression of mutant proteins, enzyme activity assay, restriction-endonuclease analysis of family members\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — active-site mutagenesis (naturally occurring) with direct enzyme activity assay confirming loss of function, validated in two unrelated patients\",\n      \"pmids\": [\"8808595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Mgat2-null mice are deficient in GlcNAcT-II enzyme activity and complex N-glycan synthesis in tissues, resulting in severe gastrointestinal, hematologic, and osteogenic abnormalities and early post-natal lethality; kidney N-glycan analysis revealed a novel bisected hybrid N-glycan in which the bisecting GlcNAc was substituted with β1,4-galactose or Lewis(x), demonstrating the essential role of MGAT2 in complex N-glycan biosynthesis in vivo.\",\n      \"method\": \"Mgat2 homozygous deletion mouse model; enzyme activity assay in tissues; N-glycan structural analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with direct enzyme activity assay and N-glycan structural analysis confirming loss of complex N-glycan synthesis\",\n      \"pmids\": [\"12417412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MGAT2 physically interacts with DGAT2 via co-immunoprecipitation and in situ proximity ligation assay; deletion mutagenesis showed the interaction depends on the two transmembrane domains of DGAT2. When co-expressed, MGAT2 and DGAT2 co-localize in the ER and on lipid droplets and co-expression increases TG storage compared with either enzyme alone, suggesting substrate channeling for TG biosynthesis.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, deletion mutagenesis of DGAT2, chemical cross-linking (DSS), co-localization imaging, TG storage quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus proximity ligation assay plus mutagenesis plus functional TG storage readout, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"25164810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MGAT2 deficiency (MGAT2-KO mice) prevents hypertriglyceridemia and significantly suppresses the rise in plasma GIP following oral triglyceride loading, while GLP-1 and PYY responses remain comparable to wild-type, demonstrating that MGAT2-dependent triglyceride re-synthesis (and/or chylomicron secretion) is required for GIP release but not for GLP-1/PYY release after fat ingestion.\",\n      \"method\": \"MGAT2-KO mouse model; oral triglyceride tolerance test; plasma gut peptide measurements (GIP, GLP-1, PYY)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with defined hormonal phenotype readout and comparison to DGAT1-KO, single lab\",\n      \"pmids\": [\"19732742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Myeloid-specific deletion of Mgat2 in antigen-presenting cells (APCs) reduces multi-antennary complex N-glycans on the cell surface and prevents glycoantigen (polysaccharide) presentation and T cell activation in vitro and in vivo, without affecting protein antigen responses, TLR2 signaling, antigen uptake, or cellular homing to lymph nodes; this establishes that complex N-glycan branching on APCs regulates MHC class II-dependent glycoantigen presentation.\",\n      \"method\": \"Myeloid-specific Mgat2 conditional knockout mouse (LyzM-CRE); in vitro and in vivo T cell activation assays; antigen uptake assay; lymph node homing assay\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO with multiple defined functional readouts, single lab\",\n      \"pmids\": [\"24310166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The human MGAT2 promoter contains functional Ets-binding sites; co-transfection of ets-1 or ets-2 expression plasmids with MGAT2 promoter-CAT reporter constructs in HepG2 or COS-1 cells stimulated promoter activity 2–4-fold. Mobility-shift assays and South-Western blots localized the functional Ets-binding site to one of four putative sites. Unlike the GnT-V promoter, the MGAT2 promoter is not activated by src or neu.\",\n      \"method\": \"Transient transfection reporter assay, electrophoretic mobility shift assay (EMSA), South-Western blot\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus reporter assay plus negative controls (src/neu non-activation), single lab\",\n      \"pmids\": [\"10749681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The MGAT2 gene has multiple transcription initiation sites and lacks a TATA box but contains a CCAAT box and multiple Sp1 consensus sites in a GC-rich promoter typical of housekeeping genes; a region between -636 and -553 bp relative to the ATG is the main promoter region, as its deletion dramatically decreased reporter gene activity in transient transfection experiments.\",\n      \"method\": \"5'-RACE, RNase protection, 3'-RACE, transient transfection of promoter-CAT deletion constructs in HeLa cells\",\n      \"journal\": \"Glycoconjugate journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter deletion series in transfection assay plus 5'/3'-RACE mapping, single lab, multiple methods\",\n      \"pmids\": [\"9579808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Conditional deletion of Mgat2 in spermatogonia (via Stra8-iCre) causes a block in spermatogenesis largely prior to round spermatid formation, leading to male infertility; Mgat2-null germ cells fail to bind L-PHA and GSA-II lectins (confirming loss of complex N-glycans), and RNA-seq showed downregulation of genes required for sperm formation. Western blot confirmed increased AKT and ERK1/2 signaling in Mgat2-null germ cells, distinct from the reduced ERK and unchanged AKT seen in Mgat1-null germ cells.\",\n      \"method\": \"Conditional KO mouse (Stra8-iCre); lectin binding assay; RNA-seq; Western blot for AKT and ERK1/2 phosphorylation; histology\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with multiple orthogonal readouts (lectin binding, transcriptomics, signaling pathway Western blot), single lab\",\n      \"pmids\": [\"39364139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MGAT1 and MGAT2 form homo- and heteromeric complexes in the ER and Golgi of living mammalian cells; bioluminescence imaging using split-luciferase (NanoBiT) complementation detected both MGAT1-MGAT1 and MGAT1-MGAT2 interactions and visualized ER-to-Golgi transitions of these complexes.\",\n      \"method\": \"NanoBiT split-luciferase complementation assay; bioluminescence subcellular imaging in living cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — split-luciferase PPI assay with subcellular imaging, single lab, single method\",\n      \"pmids\": [\"39083973\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MGAT2 encodes two distinct enzymatic activities depending on context: in the Golgi, it functions as UDP-GlcNAc:α-6-D-mannoside β-1,2-N-acetylglucosaminyltransferase II (GnT-II), an essential step in converting oligomannose to complex N-glycans (required for neurological development, immune glycoantigen presentation, and spermatogenesis); in the small intestine endoplasmic reticulum, it acts as an acyl-CoA:monoacylglycerol acyltransferase (MGAT) catalyzing diacylglycerol synthesis for triglyceride re-synthesis and dietary fat absorption, forming a physical complex with DGAT2 via DGAT2's transmembrane domains to channel lipid substrates for efficient TG biosynthesis, and modulating gut hormone (GIP) release and energy expenditure.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MGAT2 is a bifunctional gene whose product carries out two mechanistically distinct enzymatic activities in different subcellular and tissue contexts. In the Golgi it functions as N-acetylglucosaminyltransferase II (GnT-II), a 447-residue type II transmembrane enzyme with a short cytoplasmic tail, a signal-anchor transmembrane domain, and a C-terminal catalytic domain that transfers GlcNAc onto the α-6-mannose arm of N-glycans, the committed step converting oligomannose to complex N-glycans [#3]. This activity is essential in vivo: Mgat2-null mice lose complex N-glycan synthesis and develop severe gastrointestinal, hematologic, and osteogenic defects with early postnatal lethality [#5], and loss-of-function point mutations in the catalytic domain abolish GnT-II activity and cause congenital disorder of glycosylation type IIa (CDG-IIa) in humans [#4]. Complex N-glycan branching generated by MGAT2 is required for distinct cellular programs: in antigen-presenting cells it enables MHC class II-dependent glycoantigen presentation and T-cell activation [#8], and in spermatogonia it is required for progression through spermatogenesis, with its loss derepressing AKT and ERK1/2 signaling and blocking round spermatid formation [#11]. Separately, MGAT2 acts in the intestinal ER as an acyl-CoA:monoacylglycerol acyltransferase that synthesizes diacylglycerol from monoacylglycerol and fatty acyl-CoA, with an additional intrinsic DGAT activity distinguishable by detergent sensitivity [#0, #1]. In this role it physically associates with DGAT2 through DGAT2's transmembrane domains, co-localizing at the ER and lipid droplets to channel substrates for triglyceride synthesis [#6], and MGAT2-dependent triglyceride re-synthesis is required for postprandial GIP secretion after dietary fat [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established the molecular identity, domain architecture, and chromosomal locus of the glycosyltransferase GnT-II and confirmed its catalytic product, defining the enzyme that commits N-glycans to the complex pathway.\",\n      \"evidence\": \"Genomic cloning, baculovirus/Sf9 purification, in vitro assay, NMR/MS product identification, and FISH mapping\",\n      \"pmids\": [\"7635144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic structure of the catalytic domain\", \"Mechanism of acceptor mannose-arm recognition not resolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Linked MGAT2 to human disease by showing catalytic-domain point mutations inactivate GnT-II, establishing it as the causal gene for CDG type IIa.\",\n      \"evidence\": \"Patient mutation identification with baculovirus expression of mutant proteins and enzyme activity assays in two unrelated families\",\n      \"pmids\": [\"8808595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype range across CDG-IIa patients not addressed\", \"How partial loss of branching produces specific clinical features unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Characterized the MGAT2 promoter as a TATA-less, GC-rich housekeeping-type promoter, addressing how the gene is constitutively transcribed.\",\n      \"evidence\": \"5'/3'-RACE, RNase protection, and promoter-CAT deletion series in HeLa cells\",\n      \"pmids\": [\"9579808\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specific regulation not addressed\", \"Identity of trans-acting factors at the core promoter not resolved here\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified Ets transcription factors as activators of MGAT2 transcription and distinguished its regulation from GnT-V, beginning to define upstream control of branching enzyme expression.\",\n      \"evidence\": \"Reporter co-transfection, EMSA, and South-Western blot with src/neu negative controls in HepG2/COS-1 cells\",\n      \"pmids\": [\"10749681\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contexts driving Ets-dependent induction unknown\", \"Only one of four candidate Ets sites mapped as functional\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated in vivo that MGAT2 is indispensable for complex N-glycan biosynthesis and organismal viability, and revealed compensatory novel glycan structures in its absence.\",\n      \"evidence\": \"Mgat2-null mouse with tissue enzyme assays and kidney N-glycan structural analysis\",\n      \"pmids\": [\"12417412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific contributions to lethality not dissected\", \"Mechanism by which bisected hybrid glycans arise not detailed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Revealed an entirely separate lipid-metabolic activity, showing MGAT2 catalyzes diacylglycerol synthesis (MGAT activity) and harbors an additional intrinsic DGAT activity, reframing the gene as bifunctional.\",\n      \"evidence\": \"Heterologous expression in insect/mammalian cells and recombinant E. coli protein with in vitro assays, detergent discrimination, and substrate specificity/cofactor panels\",\n      \"pmids\": [\"12621063\", \"12576479\", \"12730219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single protein partitions between Golgi glycosyltransfer and ER acyltransferase functions is unexplained\", \"Physiological relevance of the intrinsic DGAT activity in vivo not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected MGAT2-dependent triglyceride re-synthesis to postprandial endocrine signaling, showing it is selectively required for GIP but not GLP-1/PYY secretion after dietary fat.\",\n      \"evidence\": \"MGAT2-KO mouse oral triglyceride tolerance test with plasma gut peptide measurements\",\n      \"pmids\": [\"19732742\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the effect is due to TG re-synthesis per se or chylomicron secretion not separated\", \"Cell-autonomous role in enteroendocrine cells not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a function for complex N-glycan branching in immunity, showing MGAT2-dependent branching on antigen-presenting cells is required for MHC class II-dependent glycoantigen presentation.\",\n      \"evidence\": \"Myeloid-specific (LyzM-Cre) conditional Mgat2 knockout with T-cell activation, antigen uptake, and homing assays\",\n      \"pmids\": [\"24310166\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which surface glycoproteins mediate the effect not identified\", \"Mechanism linking branching to glycoantigen loading not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Provided a structural mechanism for efficient triglyceride synthesis by showing MGAT2 physically partners with DGAT2 via DGAT2 transmembrane domains, supporting substrate channeling at the ER/lipid droplet.\",\n      \"evidence\": \"Reciprocal Co-IP, proximity ligation, DSS cross-linking, DGAT2 deletion mutagenesis, co-localization imaging, and TG storage quantification\",\n      \"pmids\": [\"25164810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct evidence of metabolite channeling (vs. co-localization) not shown\", \"Stoichiometry and architecture of the complex unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended the in vivo importance of MGAT2 branching to spermatogenesis and revealed that loss alters intracellular signaling, distinguishing MGAT2 from MGAT1.\",\n      \"evidence\": \"Stra8-iCre conditional KO with lectin binding, RNA-seq, histology, and Western blot for AKT/ERK1/2\",\n      \"pmids\": [\"39364139\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Glycoprotein substrates controlling germ cell signaling not identified\", \"Causal link between altered AKT/ERK and the spermatogenic block not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Began to define the supramolecular organization of branching enzymes by detecting MGAT1-MGAT2 hetero- and homomeric complexes and their ER-to-Golgi trafficking in living cells.\",\n      \"evidence\": \"NanoBiT split-luciferase complementation with bioluminescence subcellular imaging\",\n      \"pmids\": [\"39083973\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-method PPI evidence without orthogonal validation\", \"Functional consequence of MGAT1-MGAT2 heteromers for glycan processing unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single MGAT2 polypeptide is partitioned and regulated between its Golgi glycosyltransferase role and its ER lipid acyltransferase role remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No mechanism reconciling dual localization and dual catalytic functions\", \"No structural model integrating GnT-II and MGAT/DGAT activities\", \"Relative physiological weighting of the two functions across tissues unquantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [3, 0, 1]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0016747\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [3, 12]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [6, 12]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"complexes\": [\"MGAT2-DGAT2 complex\", \"MGAT1-MGAT2 heteromer\"],\n    \"partners\": [\"DGAT2\", \"MGAT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}